Clinical trials: Heart Failure NYHA Class IV
Congestive Heart Failure
Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure
The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers.
- Trial name
- NCT00063687
- Testing
- Oxypurinol
- Where
- 4 sites in United States
- Volunteers
- 400 people
- Sponsor
- Advanz Pharma
Heart Failure NYHA Class I, Heart Failure NYHA Class II
Future Patient - Telerehabilitation of Heart Failure Patients
The idea behind the Future Patient research project is to develop a telerehabilitation program and tools for patients with heart failure.
- Conditions
- Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT03388918
- Testing
- Telerehabilitation
- Where
- Denmark
- Volunteers
- 140 people
- Sponsor
- Aalborg University
Chronic Heart Failure, Heart Failure NYHA Class II
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
The purpose of this study is to investigate the effect of an early, coordinated rehabilitation intervention for patients with severe heart failure in NYHA class III and IV with a ejection fraction of <40% of normal cardiac…
- Conditions
- Chronic Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT01669395
- Testing
- Early homebased rehabilitation after hospital admission, Usual care
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Heart Failure
C-Pulse Implantable Counterpulsation Pump (ICP) - A Heart Assist Device
The C-Pulse Study is evaluating the safety and performance of a new product for the treatment of heart failure. The product is designed to help reduce the symptoms of heart failure and help patients function better with daily…
- Trial name
- NCT01176370
- Testing
- C-Pulse™ (Implantable Counterpulsation Therapy)
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Nuwellis, Inc.
Tricuspid Regurgitation, Heart Failure NYHA Class III
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
The use of implantable left ventricular assist devices (LVAD) has increased over the last decade; partly because the newer continuous flow pumps feature a smaller design and better durability.
- Conditions
- Tricuspid Regurgitation, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT02537769
- Testing
- Left ventricular assist device (LVAD), Tricuspid Valve Repair (TVR)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Remission From Stage D Heart Failure
The purpose of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function after undergoing a standardized Left Ventricular Assist Device (LVAD) plus pharmacologic recovery…
- Trial name
- RESTAGE-HF (NCT01774656)
- Testing
- Pharmacological Treatment
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Louisville
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Feasibility Study of the Intravascular Ventricular Assist System (iVAS)
The purpose of this feasibility study is to assess the preliminary safety and clinical performance of the intravascular ventricular assist system (iVAS).
- Trial name
- NCT02645539
- Testing
- intravascular ventricular assist system (iVAS)
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- NuPulseCV
Heart Failure
Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Participants
This is a single-arm, open label, interventional, multi-center, phase 4 pilot study.
- Trial name
- Biso-CHF (NCT03026088)
- Testing
- Bisoprolol
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Heart Failure, Heart Transplantation
Medical Care Versus Ventricular Assist Device for the Management of End-stage Heart Failure (MEVADE)
End-stage heart failure (ESHF) represents a major burden in terms of quality of life, mortality and costs. The current practice in France is to treat patients with ESHF by a combination of drugs and lifestyle interventions before…
- Conditions
- Heart Failure, Heart Transplantation, Heart-Assist Devices
- Trial name
- MEVADE (NCT03105726)
- Volunteers
- 224 people
- Sponsor
- Joe Elie Salem
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Heart Failure
TRI-V Heart Failure (HF) Implanted Cardioverter Defibrillator (ICD) Study
It's the aim of this study to investigate the impact of Right Ventricular (RV) lead position (RV-apex, His bundle area, RV-apex+His bundle area) in combination with individually optimized Left Ventricular (LV) lead placement and…
- Trial name
- TRI-V (NCT00746135)
- Testing
- Device Implantation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Abbott Medical Devices
Heart Failure，Congestive, Heart Failure New York Heart Association Class IV
Nicotinamide Riboside in LVAD Recipients
While preliminary data show that oral nicotinamide riboside (NR) supplementation increases myocardial levels of oxidized nicotine-adenine dinucleotide (NAD+) levels in mice, there has been no direct evidence that suggests oral NR…
- Conditions
- Heart Failure，Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration
- Trial name
- PilotNR-LVAD (NCT03727646)
- Testing
- Nicotinamide riboside
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Heart Failure, Heart Failure NYHA Class III
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
The purpose of this early feasibility study is to evaluate the safety and feasibility of the device for percutaneous shunting of the interatrial septum and improvement of heart failure related symptoms.
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
- Trial name
- EASE HF2 (NCT06859970)
- Testing
- PAS-C System
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- InterShunt Technologies, Inc.
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Cardiac Failure
Renal Artery Denervation in Chronic Heart Failure
Heart failure is a common condition with debilitating symptoms and a poor prognosis. Patients with heart failure have a massively overactive sympathetic nervous system which attempts to compensate for their poorly functioning…
- Trial name
- REACH-Pilot (NCT01584700)
- Testing
- Renal Artery Denervation
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Assessment of the Effectiveness, Socio-economic Impact and Implementation of a Digital Solution for Severe Patients
ADLIFE is a EU-funded project developing innovative digital health solutions to support healthcare planning and care delivery for patients with advanced chronic conditions (chronic obstructive pulmonary disease and/or heart…
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Chronic Obstructive Pulmonary Disease Severe
- Trial name
- ADLIFE (NCT05575336)
- Testing
- ADLIFE intervention
- Where
- 7 sites in Denmark, Germany and 3 more
- Volunteers
- 185 people
- Sponsor
- Biosistemak Institute for Health Systems Research
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy
Study of Default Options in Advance Directives
Default options represent the events or conditions that are set into place if no alternatives are actively chosen. The setting of default options has well-established effects on a broad range of human decisions, but its influence…
- Conditions
- COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy
- Trial name
- NCT01817686
- Testing
- Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Heart Failure, Left Bundle-Branch Block
Mid-Q Response Study
The Mid-Q Response study is a prospective, multi-center, randomized controlled, interventional, single-blinded, post-market study.
- Conditions
- Heart Failure, Left Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure NYHA Class II
- Trial name
- NCT04180696
- Testing
- aCRT ON, aCRT OFF
- Where
- 61 sites in Brunei, China and 8 more
- Volunteers
- 177 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.
- Trial name
- NCT05236673
- Testing
- JARDIANCE®
- Where
- 21 sites in South Korea
- Volunteers
- 676 people
- Sponsor
- Boehringer Ingelheim
Congestive Heart Failure
Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure
Aliskiren is a potent direct renin inhibitor and has been recently shown to have favorable neurohumoral effects in patients with heart failure (HF) Objective：To study the effects of add-on aliskiren treatment in patients with HF…
- Trial name
- NCT01040494
- Testing
- Aliskiren
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital